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The aim of this study was to describe the clinical characteristics of ANCA-associated vasculitides (AAV) at presentation, in a wide
cohort of Spanish patients, and to analyze the impact of the vasculitis type, ANCA specificity, prognostic factors, and treatments
administered at diagnosis, in the outcome.
A total of 450 patients diagnosed between January 1990 and January 2014 in 20 Hospitals from Spain were included. Altogether,
40.9% had granulomatosis with polyangiitis (GPA), 37.1%microscopic polyangiitis (MPA), and 22% eosinophilic granulomatosis with
polyangiitis (EGPA). The mean age at diagnosis was 55.6±17.3 years, patients with MPA being significantly older (P<0.001). Fever,
arthralgia, weight loss, respiratory, and ear–nose–throat (ENT) symptoms, were the most common at disease onset. ANCAs tested
positive in 86.4% of cases: 36.2% C-ANCA-PR3 and 50.2% P-ANCA-MPO. P-ANCA-MPO was significantly associated with an
increased risk for renal disease (OR 2.6, P<0.001) and alveolar hemorrhage (OR 2, P=0.010), while C-ANCA-PR3 was significantly
associated with an increased risk for ENT (OR 3.4, P<0.001) and ocular involvement (OR 2.3, P=0.002). All patients received
corticosteroids (CS) and 74.9% cyclophosphamide (CYC). The median follow-up was 82 months (IQR 100.4). Over this period
39.9% of patients suffered bacterial infections and 14.6% opportunistic infections, both being most prevalent in patients with high-
cumulated doses of CYC and CS (P<0.001). Relapses were recorded in 36.4% of cases with a mean rate of 2.5±2.3, and were
more frequent in patients with C-ANCA-PR3 (P=0.012). The initial disease severity was significantly associated with mortality but not
with the occurrence of relapses. One hundred twenty-nine (28.7%) patients (74 MPA, 41 GPA, 14 EGPA) died. The mean survival
was 58 months (IQR 105) and was significantly lower for patients with MPA (P<0.001). Factors independently related to death were
renal involvement (P=0.010), cardiac failure (P=0.029) and age over 65 years old (P<0.001) at disease onset, and bacterial
infections (P<0.001). An improved outcome with significant decrease in mortality and treatment-related morbidity was observed in
patients diagnosed after 2000, and was related to the implementation of less toxic regimens adapted to the disease activity and
stage, and a drastic reduction in the cumulated CYC and CS dose.
Abbreviations: AAV = ANCA-associated vasculitis, ANCA = antineutrophil cytoplasmatic antibody, anti-MPO =
antimyeloperoxidase, anti-PR3 = antiproteinase 3, BVAS = Birmingham Vasculitis Activity Score, CI = confidence interval, CRP
= C-reactive protein, CS = corticosteroids, CYC = cyclophosphamide, eGFR = estimated glomerular filtration rate, EGPA =
eosinophilic granulomatosis with polyangiitis, ELISA = antigen-specific enzyme-linked immunosorbent assay, ENT = ear, nose, and
throat, ESR = erythrocyte sedimentation rate, FFS = Five Factors score, GPA = granulomatosis with polyangiitis, IIF = indirectditor: Raouf Hajji.
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ANCA-associated vasculitides (AAV) are chronic and relapsing
autoimmune diseases, characterized by necrotizing small-vessels
inflammation and circulating antineutrophil cytoplasmic auto-
antibodies (ANCA) in 60% to 90% of patients at disease
onset.[1–9]
AAV have been classified according to their clinical phenotype,
histological findings, and ANCA specificity.[1–4] Three different
clinical forms have been differentiated: granulomatosis with
polyangiitis (GPA) formerly known as Wegener granulomatosis
(WG), eosinophilic granulomatosis with polyangiitis (EGPA)
formerly known as Churg–Strauss syndrome (CSS), and
microscopic polyangiitis (MPA). Two fluorescence patterns of
ANCAs distinguished by indirect immunofluorescence (IIF) have
been associated with AAV: the cytoplasmic-staining pattern (C-
ANCA) and the perinuclear-staining pattern (P-ANCA). Most
patients with C-ANCA by IIF have ANCAs directed against
proteinase-3 (PR3) by antigen-specific enzyme-linked immuno-
sorbent assay (ELISA), while most patients with P-ANCA by IIF
have ANCAs directed against myeloperoxidase (MPO). The
combination of C-ANCA-PR3 predominates in patients with
GPA, whereas the combination of P-ANCA-MPO is predomi-
nant in MPA and EGPA.[1]
AAV may occur at any age, with varied and overlapping
clinical manifestations at presentation that usually affect more
than one organ and make difficult to perform a definitive
diagnosis quickly.[1–9] Disease severity ranges from life organ-
threatening manifestations to milder forms, and early and
appropriate immunosuppressive treatment is crucial to reduce
death by major-organ failure and long-term morbidity. The
introduction of immunosuppressive therapy with corticosteroids
(CS) and cyclophosphamide (CYC) in the 1960s led to a dramatic
improvement in AAV prognosis, with over 90% of patients
achieving remission compared with a 1-year mortality rate
of 80% in untreated patients.[5] However, this therapy was
associated with a substantial degree of toxicity.[6–9] In order to
reduce treatment-related adverse events, the European Vasculitis
Study Group (EUVAS) standardized the definitions and assess-
ment of AAV, and defined 4 stages of the disease according to
severity and extent at presentation, tailoring treatment regimens
to the different stages[10,11]. Nonetheless, despite these advances,
there is still considerable morbidity associated with both the
disease and its treatment, that increases over time, as well as an
increased mortality compared with the general population.[12,13]
The main clinical and pathological features of AAV have been
documented in several studies from different countries, but series
derived from Spain are scarce and involve a small number of
cases.[14–20] Based on the National Spanish Network of the
Internal Medicine Society (SEMI) for systemic vasculitis study,
here we describe the clinical and pathological characteristics at
the disease onset of the largest cohort of patients derived
exclusively from this region of Europe, and we analyze the long-
term outcome and the impact on the disease course of the
vasculitis type, the ANCA specificity, prognostic factors, and
treatments administered at the time of diagnosis.22. Patients and methods
2.1. Study cohort
The Spanish Registry of Systemic vasculitis “REVAS” (Registro
Español de VAsculitis Sistemicas in Spanish nomenclature), was
created in 2009 by the Grupo de Enfermedades Autoinmunes
Sistémicas (GEAS), from the Spanish Internal Medicine Society
(SEMI), with the aim of compiling a large cohort of Spanish
patients with these rare diseases. By November 2015 (the
censoring date), 20 centers with substantial experience in the
management of these diseases participated in the recruitment of
more than 1500 patients with different vasculitides that were
included in the Registry. Epidemiological (including time and
cause of death), clinical, and laboratory data encompassing more
than 150 variables were collected frommedical records according
to a standardized form designed by the REVAS-StudyGroup, and
then entered into a specific database. All participating Centers
had obtained Ethics Committee approval.
In the present study, a total of 450 patients with AAV
diagnosed between January 1990 and January 2014 and
regularly followed-up until the censoring data, were retrospec-
tively analyzed. All patients met the American College of
Rheumatology (ACR) classification criteria for WG or CSS[2,3]
and the definition of GPA, MPA, and EGPA according to the
2012 revised Chapel Hill consensus criteria.[4]
The following data were collected: date/age at diagnosis;
gender; comorbidities; type of AAV; diagnosis delay (time to
diagnosis after the occurrence of the first vasculitis-related
symptoms); organ systems involvement at disease onset and
throughout the disease course; relevant laboratory data (eryth-
rocyte sedimentation rate (ESR), C-reactive protein (CRP), white
blood count (WBC), hemoglobin, serum creatinine, estimated
glomerular filtration rate (eGFR), urinalysis for urine protein,
red blood count and casts, 24-hour urine protein excretion, and
ANCA) at diagnosis and during follow-up; histopathology;
radiology examinations; duration of illness; relapses; treatment at
the time of presentation and relapses; deaths, and the likely causes
and comorbidity that may have contributed toward death.
ANCA were determined by IIF and ELISA techniques. Disease
activity at diagnosis, relapses and last visit, was assessed
according to the Birmingham Vasculitis Activity Score version
3 (BVAS v.3).[21] Permanent damage of organs was evaluated
according to the Vasculitis Damage Index (VDI). The Five factors
score (FFS) developed by the French Vasculitis Study Group[22]
was determined for each patient as a prognostic score.
For analysis, severity of organ involvement was defined as the
presence of one or more items within each category of the BVAS
v.3 form (systemic; cutaneous; mucous membranes and eyes; ear,
nose, and throat (ENT); chest; cardiovascular; gastrointestinal
tract; kidney and nervous system). Renal disease was defined
as the presence of hematuria >10RBCs/hpf, proteinuria >1g,
hypertension, creatinine >125mmol or rise in creatinine >30%,
or creatinine clearance fall >25%, attributable only to vasculitis,
as per the BVAS form. Acute renal failure was defined by the
presence of progressively raised serum creatinine or 15%
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days or weeks. eGFR was calculated for each patient for the time
of diagnosis and for the last visit of the study period using the
modification of diet in renal disease equation. Chronic kidney
disease was defined as an eGFR <60mL/min/1.73m2. The
nervous system involvement was subdivided into central nervous
system (stroke, meningitis, cord lesion, and cranial nerve palsy)
and peripheral nervous system (sensory peripheral neuropathy
and motor mononeuritis multiplex).
According to the European recommendations,[10,11] after 2000
most patients with generalized or severe disease received
intravenous pulses of CYC as induction therapy and switched
to other less toxic immunosuppressant drugs for maintenance
therapy. For this reason, the study was divided in 2 periods
(1990–2000 and 2001–2014) in order to analyze the influence of
the different therapeutic regimens in the disease outcome.2.2. Treatment protocols
Therapeutic regimens varied between individual patients and
hospitals, depending on the disease severity and developments in
treatment protocols over the study period. Induction therapy
consisted in CS, usually in conjunction with CYC or methotrex-
ate (MTX), though azathioprine (AZA) or mycophenolate
mofetil (MMF)were administered in some cases. Oral prednisone
was prescribed at an initial dose of 1mg/kg/day. CYC was given
daily oral (2mg/kg/day) or intravenously (0.7g/m2) every month.
MTX was given 15 to 25mg once a week, with folic acid
substitution. AZA was given 1 to 2mg per kg body weight per
day, andMMF 2g daily. Patients with severe disease received 3 to
5 consecutive intravenous pulses of methyl-prednisolone (7–15
mg/kg/day) before standard induction treatment. Some patients
with severe alveolar hemorrhage or rapidly progressive glomer-
ulonephritis received additionally plasma exchange (PE).
Intravenous immunoglobulin (IVIG) or Rituximab (RTX) were
administered in some refractory cases. Oral or intravenous
CYC, MTX, AZA, or MMF were given as maintenance
treatment in conjunction with CS according to the attending
physician’s discretion, for at least 18 months after remission
had been achieved. There was no strict protocol for
trimethoprim–sulfamethoxazole (TM-SX) prophylaxis for
Pneumocystis jiroveci.
Remission was defined as the absence of clinical and laboratory
evidence of vasculitis activity. Relapses were defined as
recurrence of signs or new symptoms after an initial remission
had been achieved. Uncontrolled vasculitis was defined as the
occurrence of new manifestations or aggravation of manifes-
tations already present despite treatment for the disease.2.3. Statistical analysis
This was a multicenter observational, longitudinal-retrospective
study. Categorical data were summarized as percentages;
significant differences or associations were analyzed using the
x2 test or Fisher exact tests. Continuous variables are presented as
mean± standard deviation (SD) or median and interquartile
range (IQR), depending on normality demonstrated by
Kolmogorov–Smirnov test. Associations of quantitative data
were analyzed with Student t test and with the nonparametric
Mann–Whitney U test or the Kruskal–Wallis test. For mortality
analyses, independent variables that appeared to have statistical
significance in the univariate analysis were included in a
multivariate logistic regression model using a backward stepwise3method. The odds ratios (OR) and their 95% confidence interval
(CI) obtained in the adjusted regression analysis were calculated.
Survival curves were constructed according to the Kaplan–Meier
method and compared using the log-rank test. For all the
statistical analyses, P<0.05 was considered significant. Statisti-
cal analysis was performed using the SPSS package (IBM Corp.
2010, Armonk, NY, SPSS Statistics 19.0).3. Results
3.1. Demographics of all patients at baseline
Four hundred fifty patients (50.4% males) were included in the
study: 184 (40.9%) with GPA, 167 (37.1%) with MPA and 99
(22%) with EGPA. Mean age at disease onset was 55.6±17.3
years (range 17–91 years), 35.1% of patients being older than
65 years at disease onset. Altogether, 30.7% of patients had
hypertension, 9.8% diabetes, and 18.2% hypercholesterolemia,
beforeAAVdiagnosis. Themedian diagnostic delaywas 3months
(IQR2–5).However, 14.2%of patients were diagnosed 6months
after the occurrence of the first vasculitis-related symptoms,
and 6% of patients after more than 12 months, mainly those
patients with granulomatous forms of GPA. Demographic data,
mean BVAS score at diagnosis, and number of relapses and
deaths, for the whole cohort and each type of AAV, are shown in
Table 1.
3.2. Clinical characteristics of all patients at diagnosis
Nonspecific symptoms such as fever, fatigue, joint pain, and
weight loss were present at diagnosis in over 50% of cases. Renal
involvement was detected in 279/450 (62%) patients, hematuria
being the most common initial finding (227/279, 81.4%),
followed by renal insufficiency (183/279, 40.7%). Severe renal
failure (creatinine≥500mmol/L) was present in 30/279 (6.7%)
patients, proteinuria ≥1g in 99/279 (35.5%), and nephrotic
syndrome in 35/279 (12.5%). Renal biopsy was performed in
164/279 (58.8%) cases and showed a crescent glomerulonephri-
tis in 140/164 (85.3%). Lung involvement was present in 245
(54.5%) patients, of whom 84 (34.3%) had hemoptysis, and 90
(36.7%) respiratory failure, 22 (8.9%) of them needing
mechanical ventilation, mostly due to alveolar hemorrhage.
Chest X-ray and thorax computed tomography showed alveolar
infiltrates or interstitial lung disease in 193/245 (78.8%) of
patients, and isolated or multiple lung nodules in 106/245
(43.3%). A pulmonary-renal syndrome was observed in 74/450
(16.4%) cases. Neurological involvement was detected in 156/
450 (34.7%) patients, of whom 80 (51.3%) had mononeuritis
multiplex, 64 (41%) sensory peripheral neuropathy, and 22
(14.1%) cerebrovascular accidents. Cardiac involvement was
recorded in 58/450 (12.9%) patients, with pericarditis in
12 (20.7%) of them, cardiomyopathy in 10 (17.2%), coronary
artery involvement in 16 (27.6%), and congestive cardiac failure
in 33 (56.9%). Two patients developed an acute aortic
insufficiency and required surgical intervention. Gastrointestinal
involvement manifested by vomiting, abdominal pain, or bloody
diarrhea was present in 20/450 (4.4%) patients. ENT involve-
ment manifested by sinusitis, hearing loss, or bloody nasal crusts
was found in 203/450 (45.1%) patients. Skin involvement
manifested by palpable purpura, maculopapular rash, or
erythematous nodules was found in 112/450 (24.9%) patients,
and ophthalmic involvement manifested by conjunctivitis,
episcleritis, anterior uveitis, retinal vasculitis, or optical nerve
vasculitis, in 60/450 (13.3%). Mean BVAS at the time of
Table 1
Demographic and epidemiological characteristics at baseline of the total cohort and each type of AAV.
All patients (n=450) GPA (n=184) MPA (n=167) EGPA (n=99) P
Men/women, no. 227/223 94/90 84/83 49/50 0.96
Mean age, y (mean±SD) 55.6±17.3 49.9±16.3 63.8±16.2 52.6±15.8 <0.001
Age≥65 y at diagnosis (%) 158 (35.1%) 39 (25%) 95 (56.9%) 24 (24.2%) <0.001
Smokers, no. (%) 81 (18) 38 (20.7) 32 (19.2) 11 (11.2) 0.34
Hypertension, no (%) 138 (30.7) 40 (21.7) 72 (43.1) 26 (26.3) 0.001
Diabetes, no. (%) 44 (9.8%) 16 (8.7) 20 (12.0) 8 (8.1) 0.05
Hypercholesterolemia, no. (%) 82 (18.2) 33 (17.9) 26 (15.0) 23 (23.2) 0.29
Asthma, no. (%) 114 (25.3) 15 (8.2) 8 (4.8) 91 (91.9) <0.001
Diagnostic delay, mo (median, IQR) 3 (2–5) 3 (2–6) 2 (1.2–4) 4 (1.5–6) 0.006
BVAS (mean±SD) 17.8±7.7 18.2±9.2 17.9±7.5 16.4±6.7 0.10
Relapses≥1, no. (%) 164 (36.4) 77 (41.3) 58 (34.7) 29 (29.3) 0.005
Number of relapses (mean±SD) 2.5±2.3 1.5±2.5 1±1.7 1±1.5 0.005
Deaths, no. (%) 129 (28.7) 41 (22.3) 74 (44.3) 14 (14.1) <0.001
Time to death, mo (median, IQR) 58 (105) 73 (135) 50 (67) 114 (129) <0.001
AAV= antineutrophil cytoplasmatic antibody-associated vasculitis, BVAS=Birmingham Vasculitis Activity Score, EGPA= eosinophilic granulomatosis with polyangiitis, GPA=granulomatosis with polyangiitis,
IQR= interquartile range, MPA=microscopic polyangiitis, SD= standard deviation.
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gender-related differences in terms of clinical symptoms and
BVAS were observed. Clinical characteristics of the entire cohort
and each type of AAV are summarized in Tables 1 and 2.
3.3. Laboratory data of all patients at baseline
ESR and CRP values were increased in more than 75%of patients
at the time of diagnosis and serum creatinine was raised in 40.7%
of patients, with amean serum creatinine at presentation of 2.03±
2.1mg/dL (range: 0.3–16.5mg/dL). Normochromic anemia was
present in 68.2%of cases.ANCAtestedpositive in 86.4%of cases:
36.2% C-ANCA-PR3 and 50.2% P-ANCA-MPO. Laboratory
data are summarized in Tables 2–4.
A total of 521 biopsies (renal, muscle, nerve, skin, nose, ear,
throat, liver, intestine, meninges) were done. The diagnosis of
vasculitis was supported by histopathology in 368 (81.8%) cases. In
the remaining cases, the diagnosis was made on the basis of typical
clinical symptoms in conjunction with a positive ANCA test.
3.4. Treatment
Almost all patients received daily oral prednisone (1mg/kg/day)
that was gradually tapered depending on the clinical response
and the evolution of laboratory parameters. Intravenous
methylprednisolone (3–5 consecutive pulses) was administered
to 237 (52.7%) patients with severe disease. For induction
therapy 334 (74.2%) patients received CYC (daily oral 168/334,
50.3%), 27 (7.7%) MTX, 19 (4.2%) AZA, and 5 (1.1%) MMF.
Additionally, 26 (5.8%) patients received RTX after CYC failure.
For maintenance therapy, 143 (31.8%) patients received AZA,
118 (26.2%) CYC (47 IV pulses and 71 oral), 49 (10.9%) MTX,
42 (9.3%) MMF, and 24 (5.3%) RTX. TMT-SX prophylaxis
(one 400mg tablet/day or 800mg tablet every 2 days) was
maintained in 213 (47.3%) patients. Dialysis was required in 60
(13.3%) cases.
3.5. Comparison between MPA, GPA, and EGPA
Patients with MPA were significantly older at diagnosis than
patients with GPA and EGPA (P<0.001). Kidney involvement
and pulmonary-renal syndrome were more prevalent in patients
with MPA (P<0.001), neurological and cardiac involvement in4patients with EGPA (P<0.001), and ENT and ocular involve-
ment in patients with GPA (P<0.001). Of note, 91.9% of
patients with EGPA had asthma, with a median period of 60
months (IQR 96) between asthma and vasculitis development.
Median BVAS at diagnosis was similar in GPA,MPA, and EGPA.
The median time to diagnosis was significantly greater in
patients with GPA and EGPA (P=0.006). Clinical characteristics
at disease onset and demographic data are depicted in Tables 1
and 2.
Concerning the laboratory data (Tables 2–4), anemia was
more prevalent in patients with MPA (89.2%) than in those with
GPA (64.7%) and EGPA (39.4%), P<0.001; serum creatinine
values were higher in patients with MPA than in those with GPA
and EGPA (P<0.001), and the mean eGFRwas lower in patients
withMPA (P=0.006). ANCA tested positive in 100% of patients
with MPA, 88.6% of patients with GPA, and 60.6% of patients
with EGPA. C-ANCA-PR3 autoantibodies were more prevalent
in patients with GPA (P<0.001), and P-ANCA-MPO in patients
with MPA and EGPA (P<0.005). The presence of P-ANCA-
MPO was associated with a significant increased risk for renal
disease (OR 2.6, 95% CI: 1.7–3.8, P<0.001) and alveolar
hemorrhage (OR 2, 95% CI: 1.8–3.8, P=0.010), while the
presence of C-ANCA-PR3 was related to a significant increased
risk for ENT involvement (OR 3.4, 95% CI: 2.3–5.1, P<0.001)
and ocular involvement (OR 2.3, 95% CI: 1.4–4.1, P=0.002).
No significant relationship was found between pulmonary-renal
syndrome and ANCA specificity.
In regard to treatment, oral CYC was more frequently
administered as induction therapy to patients with GPA (87,
47.3%) than to those with MPA (62, 37%) and EGPA (22,
2.2%), (OR 1.9, 95% CI: 1.3–2.9, P=0.001), especially to
patients with granulomatous manifestations. Similarly, TMT-SX
was more frequently given to patients with GPA than to those
withMPA and EGPA (99.5% vs 46.1% and 23.1%, respectively,
P<0.001). In contrast, dialysis was mainly required in patients
with MPA (41, 24.6%), compared to patients with GPA (18,
9.8%) and EGPA (1, 1%), P<0.001.3.6. Outcome
The median follow-up period was 82 months (IQR 104.5).
During this period, 175 (39.9%) patients had a total of 219
Table 2
Clinical characteristics and organ involvement at diagnosis in the entire cohort and in each type of AAV.
All patients (n=450) GPA (n=184) MPA (n=167) EGPA (n=99)
Pn (%) n (%) n (%) n (%)
Fever ≥38°C 237 (52.7) 96 (52.2) 87 (52.1) 54 (54.5) 0.112
Toxic syndrome 229 (50.9) 94 (51.1) 93 (55.7) 42 (42.4) 0.11
Joints involvement 252 (56.0) 106 (57.6) 93 (45.7) 53 (53.2) 0.80
Arthralgia 238 (52.9) 100 (54.3) 92 (55.1) 46 (46.5) 0.35
Arthritis 64 (14.2) 34 (18.5) 12 (7.2) 18 (18.2) 0.005
Skin involvement 112 (24.9) 47 (25.0) 28 (16.8) 37 (37.4) 0.005
Purpura 92 (20.4) 33 (17.9) 25 (15) 34 (34.3) <0.005
Cutaneous ulcers 35 (7.8) 23 (12.5) 3 (1.8) 9 (9.1) 0.001
Livedo reticularis 26 (5.8) 10 (5.4) 13 (7.8) 3 (3.0) 0.005
ENT involvement 203 (45.1) 133 (72.3) 17 (10.2) 53 (53.4) <0.001
Rhinitis 97 (21.6) 80 (43.5) 4 (2.4) 13 (13.1) <0.005
Paranasal sinus involvement 152 (33.8) 105 (57.5) 5 (3.0) 47 (47.5) <0.001
Otitis media 80 (17.8) 61 (33.2) 6 (3.6) 13 (13.1) <0.001
Sensorineural hearing loss 48 (10.7) 40 (21.7) 5 (3.0) 3 (3.0) <0.001
Lung involvement 245 (54.5) 115 (62.5) 71 (42.5) 59 (59.6) 0.001
Lung nodules 106 (23.6) 80 (43.5) 12 (7.2) 14 (14.1) <0.001
Lung infiltrates 193 (51.1) 73 (39.7) 65 (38.9) 55 (55.6) <0.005
Renal involvement 279 (62.0) 103 (56.0) 144 (86.2) 32 (32.3) <0.001
Hematuria ≥10RBCs/hpf 227 (50.5) 82 (46.2) 125 (74.9) 18 (18.2) <0.001
Renal insufficiency 183 (40.7) 57 (31.0) 115 (68.9) 12 (12.1) <0.001
Creatinine 125–249mmol 55 (12.2) 17 (9.2) 34 (20.4) 6 (6.1) <0.001
Creatinine 250–499mmol 98 (21.8) 27 (14.7) 65 (39.5) 5 (5.1) <0.001
Creatinine ≥500mmol 30 (6.7) 13 (7.1) 16 (9.6) 1 (1.0) 0.007
Proteinuria >1g 99 (35.5) 29 (18.4) 66 (42.3) 4 (4.1) 0.009
Pulmonary-renal syndrome 74 (16.4) 27 (14.7) 43 (25.7) 4 (4.1) <0.001
Neurological involvement 156 (34.7) 51 (27.7) 51 (30.5) 54 (54.5) <0.001
Mononeuritis multiplex 80 (17.8) 23 (12.5) 18 (10.8) 39 (39.4) <0.001
Sensory peripheral neuropathy 64 (14.2) 18 (9.8) 29 (17.4) 17 (17.2) <0.005
Cerebrovascular accident 22 (4.9) 11 (6.0) 9 (5.4) 2 (2.0) 0.30
Cardiac involvement 58 (12.9) 20 (10.9) 18 (10.8) 20 (20.2) <0.001
Pericarditis 12 (2.7) 3 (1.6) 3 (1.8) 6 (6.1) <0.001
Cardiomyopathy 10 (2.2) 3 (1.6) 1 (0.6) 6 (6.1) 0.046
Ischemic cardiac pain 16 (3.6) 7 (3.8) 5 (3.0) 4 (4.8) 0.88
Congestive cardiac failure 33 (7.3) 11 (6.0) 11 (6.6) 11 (11.1) <0.001
Gastrointestinal involvement 20 (4.4) 10 (5.4) 8 (4.8) 2 (2.0) 0.40
Ischemic abdominal pain 11 (2.5) 4 (2.2) 6 (3.6) 1 (1.0) 0.41
Bloody diarrhea 13 (2.9) 6 (3.3) 5 (3.0) 2 (2.0) 0.40
Ophthalmic involvement 60 (13.3) 44 (23.9) 6 (3.6) 10 (10.1) 0.001
AAV= antineutrophil cytoplasmatic antibody-associated vasculitis, EGPA= eosinophilic granulomatosis with polyangiitis, ENT= ear-nose-throat, GPA=granulomatosis with polyangiitis, MPA=microscopic
polyangiitis.
Table 3
Laboratory data at baseline.
All patients (n=450) GPA (n=184) MPA (n=167) EGPA (n=99) P
ESR, mean (SD), range, mm/h 73.8±34.4 (3–161) 74.3±35.2 (3–150) 85.2±29.2 (6–136) 54.5±32.4 (5–161) 0.002
CRP, mean (SD), range, mg/dL 10.9±9.3 (1–42) 11.8±9.1 (0.1–42) 10.9±8.6 (0.1–42) 9.1±8.7 (0.3–42) 0.101
Fibrinogen, mean (SD), range, g/L 5.7±1.9 (1.4–13) 5.8±2.1 (1.4–11) 5.9±1.9 (2.3–13) 4.9±1.7 (2.2–11) 0.056
Alpha-2 globulin, % 14.4±4 (2.1–27.6) 14.9±3.9 (6.9–27) 14.9±1.9 (6.9–24) 12.4±3.7 (2.1–22) 0.245
Hemoglobin, mean (SD), range, g/L 11.2±2 (4.6–17.3) 11.4±2.1 (5.3–17) 9.9±1.9 (4.6–16) 12.7±1.9 (6.9–17) 0.001
WBC, mean (SD), range, 109/L 12.2±5.9 (2.3–4.7) 11.0±5.2 (2.3–35) 11.2±4.3 (3.1–26.6) 15.7±7.9 (3.4–47) 0.016
Lymphocytes, mean (SD), range, 109/L 0.69±1.1 (0.4–9) 1.5±0.8 (0.4–6.2) 1.6±1.1 (0.5–8.1) 2.1±1.2 (0.6–9) 0.006
Eosinophil, % 9.9±16.8 (0–81.7) 2.5±4 (0–26) 2.3±4.5 (0–43%) 31.9±20.3 (1.6–87.6) 0.001
Platelets, mean/SD, range, 109/L 362±147.3 (29–1000) 375.2±168.6 (29–1300) 348.1±144.9 (31.3–738) 360.2±103.4 (147–694) 0.001
Serum creatinine, mean (SD), range, mg/dL 2.03±2.1 (0.3–16.5) 1.7±1.9 (0.3–12.2) 2.9±2.4 (0.4–16.5) 1.1±1.1 (0.5–9) 0.005
GRF, mean (SD), range, mL/min 59.7±31.4 (4–130) 65.4±30.1 (4–130) 41.9±27.9 (4–100) 79.6±22.4 (9–128) 0.006
Proteinuria, mean (SD), range, mg/dL 812±1293 (120–8800) 607±1015 (15–7500) 1336±1637 (27–8800) 224±309 (12–2000) 0.005
CRP=C-reactive protein, EGPA= eosinophilic granulomatosis with polyangiitis, ESR= erytrosedimentation rate, GFR=glomerular filtration rate, GPA=granulomatosis with polyangiitis, MPA=microscopic
polyangiitis, SD= standard deviation, WBC=white blood cell count.
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Table 4
ANCA specificities in patients with AAV.
All patients GPA MPA EGPA P
ANCA
Positive (n, %) 389 (86.4%) 163 (88.6%) 167 (100%) 60 (60.6%)
C-ANCA-PR3 162 (36%) 136 (73.9%) 16 (9.6%) 10 (10.2%) <0.001
P-ANCA-MPO 228 (50.6%) 27 (14.7%) 151 (90.4%) 50 (50.5%) <0.001
Negative 61 (13.6%) 21 (11.4%) — 39 (39.5%) <0.001
AAV=ANCA-associated vasculitis, ANCA= antineutrophil cytoplasm antibodies, EGPA=eosinophilic granulomatosis with polyangiitis, GPA=granulomatosis with polyangiitis, MPA=microscopic polyangiitis,
MPO=myeloperoxidase, PR3=proteinase 3.
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40 septicemia); 56 (12.4%) suffered a total of 74 opportunistic
infections (27 Candida sp., 16 other systemic mycosis, 14 P
jirovecii, 12 CMV, 5 atypical mycobacteria), and 24 (6%)
developed a solid neoplasm. Furthermore, 99 (22%) patients
developed leucopenia and 23 (5.1%) had pancytopenia.
Bacterial infections were more prevalent in patients treated
with oral CYC (OR 3.1, 95% CI: 2.1–4.6, P<0.001), patients
who received a cumulative dose of CS >7.5 in the first year of
treatment (OR 2.2 95% CI: 1.5–3.3, P<0.001), and in those
who developed leucopenia (OR 4.1 95%CI: 2.6–6.7, P<0.001).
Similarly, opportunistic infections were more prevalent in
patients who received oral CYC (OR 2.5, 95% CI: 1.4–4.4,
P=0.002), a cumulative dose of CS >7.5 in the first year of
treatment (OR 1.9, 95% CI: 1.1–3.4, P=0.034), and in those
who developed leucopenia (OR 4.6, 95% CI: 2.8–8.4, P<
0.001). Leucopenia was significantly related to oral CYC therapy
(OR 6.7, 95% CI: 4.1–11.2, P<0.001). Septicemia was more
prevalent in patients with severe renal failure who needed dialysis
(OR 4.0, 95% CI: 1.7–9.3).
A total of 164 (36.4%) patients experienced one or more
disease relapses, with a mean rate of 2.5±2.3 (range: 1–15). The
number of relapses varied according to the type of AAV (Table 1),
being more frequent in patients with GPA (P<0.005). Regarding
the ANCA specificity, patients with C-ANCA-PR3 suffered more
relapses (71/147, 48.3%) than those with P-ANCA-MPO (72/Figure 1. Long-term survival according to the type of AAV. Kaplan–Meier
curve showing an association between survival and type of AAV (P<0.001,
log-rank<0.001). EGPA=eosinophilic granulomatosis with polyangiitis, GPA
=granulomatosis with polyangiitis, MPA=microscopic polyangiitis.
6204, 35.3%), OR 1.7, 95% CI: 1.1–2.6, P=0.012. No
relationship was observed between the initial disease severity
and the occurrence of relapse (BVAS 19±8.4 in the group with
relapses and BVAS 17.3±7.5 in the group without, P=0.083).
One hundred twenty-nine (28.7%) patients died: 74 with
MPA, 41 with GPA, and 14 with EGPA. Mortality was
significantly higher in patients with MPA than in those with
GPA and EGPA (OR 3.3, 95% CI: 2.1–5.1, P<0.001). The
median time to death was 58 months (IQR 105) for the total
cohort, and was significantly lower in patients with MPA (P<
0.001), as shown in Table 1 and Fig. 1. With respect to ANCA,
mortality was significantly higher in patients with positive ANCA
at disease onset (OR 5.3, 95% CI: 2.1–13.4, P<0.001) than in
those with negative ANCA (Fig. 2), as well as in patients with P-
ANCA-MPO compared to those with C-ANCA-PR3 (OR 2.0,
95% CI: 1.2–3.04, P<0.001).
Factors associated with death in univariate and multivariate
analysis are listed in Table 5. Multivariate Cox regression
analysis identified renal involvement (OR 2.5, 95% CI: 1.2–4.9),
cardiac failure (OR 3.1, 95% CI: 1.1–8.6), and age higher than
65 years old (OR 3.1, 95% CI: 1.8–5.4) at disease onset as
independent factors related to death. Bacterial infections were
also independently related to death (OR 3.7, 95%CI: 2.1–6.6). In
contrast, ENT involvement and mortality were inversely related
(P<0.001). There were no significant differences related to
gender.Figure 2. Long-term survival according to the ANCA positivity. Kaplan–Meier
curve showing an association between survival and ANCA positivity (P<
0.001). EGPA=eosinophilic granulomatosis with polyangiitis, GPA=granulo-
matosis with polyangiitis, MPA=microscopic polyangiitis.
Table 5
Factors related to death according to univariate and multivariate analysis.
Univariate analysis Multivariate analysis
Factor Death (n, %) Alive (n, %) OR 95% CI P OR 95% CI P
Age at diagnosis >65 y 83 (64.3) 75 (23.4) 5.9 3.8–9.2 <0.001 3.1 1.8–5.4 <0.001
Renal involvement 111 (85.3) 168 (52.3) 5.6 3.3–9.7 <0.001 2.5 1.2–4.9 0.010
Cardiac failure 17 (13.2) 16 (5.0) 2.8 1.4–5.9 0.002
Stroke 11 (8.5) 11 (34.3) 2.6 1.1–6.2 0.030
Anemia 103 (79.9) 204 (63.6) 2.3 1.4–3.7 0.001
Proteinuria >1g 38 (29.5) 61 (19.0) 1.8 1.1–2.9 0.021
Positive ANCA 124 (96.1) 266 (82.7) 5.1 2.0–13.1 <0.001 4.9 1.0–23 0.049
Bacterial infections 75 (58.1) 100 (34.6) 3.1 2.1–4.8 <0.001 3.7 2.1–6.6 <0.001
Opportunistic infections 23 (17.8) 33 (10.3) 2.3 1.3–4.2 0.008
ANCA= antineutrophil cytoplasm antibodies, CI= confidence interval, OR= odds ratio.
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after 2000
A total of 135/450 (30%) patients were diagnosed before 2000.
No significant differences were noted between patients diagnosed
before and after 2000, in terms of age at diagnosis, sex,
cardiovascular risk factors, type of vasculitis, diagnosis delay,
ANCA positivity and specificity, initial clinical symptoms and
organ involvement, except for renal disease (Table 6). Indeed,
only kidney involvement was significantly more common in
patients diagnosed before 2000 than in those diagnosed later
(69.6% vs 58.7%, P=0.034).
Patients diagnosed before 2000 received more frequently oral
CYC as induction therapy than patients diagnosed after this date
(OR 3.3, 95% CI: 2.6–5.2, P<0.001). In contrast, patients
diagnosed after 2000 received more frequently IV pulses of CYC
as induction therapy than those diagnosed before 2000 (OR 2.2,
95% CI: 1.3–3.1, P=0.001), and switched to another less toxic
immunosuppressant drug (AZA, MMF) for maintenance thera-
py. This fact accounted for a reduced cumulated dose of CYC
after 2000 (Table 6). In a similar way, most patients diagnosed
after 2000 received high-dose of CS (>20mg/day) for a shorter
period of time, followed by a faster tapering, which lead to a
cumulative dose of CS<7.5g in the first year of treatment in most
cases. Indeed, before 2000, the dose of prednisone was usually
reduced by 10mg/day every 4 weeks up to 10mg/day, and then
2.5mg/day every month up to 5mg/day, whereas after 2000 the
dose was decreased more rapidly (10mg/day every 2 weeks up to
20mg/day, followed by 10mg/day every 4 weeks up to 10mg/
day, and then 2.5mg/day every month up to 5mg/day), with a
significant reduction of the total cumulative CS dose in the first
year of treatment (from an average of 7.5g before 2000 to an
average of 4.5g after 2000) (Table 6).
Bacterial infections were significantly more prevalent in
patients diagnosed before 2000 (55%) than in those diagnosed
later (33.3%) (OR 2.5, 95% CI: 1.6–3.3, P<0.001), and were
significantly related to treatment with oral CYC (P<0.001).
Finally, mortality was significantly higher in patients diag-
nosed before 2000 (48%) than in those diagnosed later (20.3%)
(OR 3.3, 95% CI: 2.34–5.61, P<0.001).
4. Discussion
This is the largest series of patients with AAV reported from
Spain. The onset, age, gender, and patterns of organ involvement
in our patients were similar to those described in themain series in
Europe and other countries,[5–9,23–29] though the mean age at the
time of diagnosis was significantly higher in patients withMPA in7our cohort, in agreement to that recently reported byMohammad
et al[24] and Sada et al.[29]
As already described,[5–9,27–29] themost common symptoms at
the disease presentation were nonspecific (fever, fatigue, joint
pain, weight loss), followed by respiratory and ENT manifes-
tations. Most patients had multisystem involvement, but
kidney and lung were the 2 most vulnerable organs to be
involved. Indeed, renal involvement was present in over 60% of
patients, and severe renal failure was the major cause for long-
term end stage organ damage. Similarly, lung involvement was
present in over 50% of patients, of whom 16.2% developed a
pulmonary-renal syndrome, pulmonary hemorrhage being the
major cause of acute respiratory failure requiring mechanical
ventilation.
In line with previous studies,[11,13,23,25–29] we found significant
differences in clinical features at disease presentation according to
the different AAV categories. In this sense, renal involvement was
almost constant in MPA but exceptional in EGPA; ENT
involvement was predominant in GPA but rare in MPA;
neurological and cardiac involvement was notably more
prevalent in EGPA than in GPA and MPA, and pulmonary-
renal syndrome was more frequent in MPA than in GPA and
exceptional in EGPA. However, these features did not allow
differentiating between the particular AAV clinical forms,
similarly to the abnormal laboratory findings present at the
time of diagnosis, which were nonspecific, though the presence of
eosinophilia strongly suggested EGPA.
With respect to ANCA, we confirmed that C-ANCA-PR3
antibodies were mainly associated with GPA, and P-ANCA-
MPO antibodies withMPA and EGPA, although this fact was not
exclusive. Thus, 14.7% of patients with GPA showed P-ANCA-
MPO, and about 10% of patients with MPA and EGPA showed
C-ANCA-PR3, in consonance with other studies.[7,25,30] This fact
emphasizes the importance of histopathology in AAV diagnosis
accuracy, to avoid misdiagnosis.[1–9,27–29] In our series, diagnosis
of vasculitis was supported by characteristic histopathologic
findings in 81.8% of cases.
The median time to diagnosis was shorter in our series than
reported in other studies,[25,27] and similar to that recently
described byMohammad et al.[24] The broad heterogeneity in the
clinical features of patients at disease onset and the absence of
ANCA, especially in limited forms of GPA and in a significant
percentage of patients with EGPA, were probably related to the
substantial delay in diagnosis observed in some cases. Misdiag-
nosis of nasal crusts and hearing loss in patients with GPA, lung
infiltrates, and skin lesions in asthmatic patients with EGPA, and
differences in the diagnosis work-up (testing for ANCA) in elderly
Table 6
Clinical, laboratory features and treatment, in patients diagnosed
before and after 2000.
<2000 >2000 P
Number of patients 135 315
GPA (n, %) 56 (40.5) 128 (40.6) 0.92
MPA (n, %) 49 (36.3) 118 (37.5) 0.83
EGPA (n, %) 30 (22.2) 69 (21.9) 1.0
Men/women (n, %) 60/75 (44.4/55.6) 167/148 (53.0/47.0) 0.10
Age at diagnosis, y (mean±SD) 54.2±18.6 56.3±16.7 0.32
Age ≥65 at diagnosis (y), % 46 (34.1) 112 (35.8) 0.75
CVR factors (n, %) 75 (62%) 164 (59.2) 0.66
Fever (n, %) 73 (54.1) 164 (52.1) 0.75
Toxic syndrome (n, %) 67 (49.6) 162 (51.4) 0.76
Joints involvement (n, %) 82 (60.7) 170 (54) 0.21
Renal involvement (n, %) 94 (69.6) 185 (58.7) 0.03
Lung involvement (n, %) 78 (57.8) 167 (53) 0.41
Pulmonary-renal syndrome (n, %) 23 (17.0) 51 (16.2) 0.89
Neurological involvement (n, %) 50 (37.0) 106 (36.1) 0.17
Heart involvement (n, %) 23 (17.0) 35 (11.1) 0.93
Peripheral nerve involvement (n, %) 46 (34.1) 95 (32.2) 0.17
Stroke (n, %) 5 (3.7) 17 (5.4) 0.68
Gastrointestinal involvement (n, %) 5 (3.7) 15 (4.8) 0.81
ENT involvement (n, %) 53 (39.3) 150 (47.6) 0.12
Ocular involvement (n, %) 24 (17.8) 37 (11.7) 0.99
Anemia (n, %) 92 (68.1) 215 (68.3) 1.00
Creatinine ≥500mmol (n, %) 14 (10.4) 16 (5.1) 0.06
Proteinuria >1g (n, %) 30 (27.0) 69 (24.1) 0.60
ANCA positive (n, %) 115 (85.2) 275 (87.3) 0.55
C-ANCA-PR3 52 (38.5) 110 (34.9) 0.56
P-ANCA-MPO 63 (46.7) 165 (52.4) 0.53
ANCA negative (n, %) 20 (14.8) 40 (12.7) 0.55
Diagnostic delay, mo (median, IQR) 4 (1.8–5) 4 (2–5) 0.21
BVAS (mean, SD) 18.2±7.9 17.5±7.7 0.39
Induction therapy
Oral CS (n, %) 134 (99.3) 310 (98.4) 0.67
Oral CYC (n, %) 75 (55.6) 93 (29.3) <0.001
IV CYC (n, %) 30 (22.2) 138 (43.8) 0.001
MTX (n, %) 5 (3.7) 22 (7.0) 0.001
AZA (n, %) 5 (3.7) 14 (4.5) 0.001
MMF (n, %) — 5 (1.6) —
Maintenance therapy
CYC (n, %) 60 (44.5) 40 (12.7) 0.001
AZA (n, %) 20 (14.8) 123 (39.0) 0.001
MTX (n, %) 13 (9.6) 36 (11.4) 0.62
MMF (n, %) 5 (3.7) 37 (11.7) 0.007
Cumulative CYC dose 39.2±31.7 16.9±23.5 0.001
Cumulative CS dose in the 1st year 7.5±3 4.5±3 0.001
Dialysis (n, %) 22 (16.3) 38 (12.1) 0.29
Bacterial infections (n, %) 73 (54.1) 102 (32.4) 0.001
Opportunistic infections (n, %) 19 (14.1) 37 (11.7) 0.34
Leukopenia (n, %) 45 (34.1) 54 (17.9) <0.001
Relapses 64 (47.4) 100 (34.0) 0.04
Deaths (n, %) 65 (48.1) 64 (20.3) <0.001
ANCA= antineutrophil cytoplasm antibodies, AZA= azathioprine, BVAS=Birmingham Vasculitis
Activity Score, CS= corticosteroids, CVR= cardiovascular risk factors, CYC= cyclophosphamide,
EGPA= eosinophilic granulomatosis with polyangiitis, ENT= ear-nose-throat, GPA=granulomatosis
with polyangiitis, IQR= interquartile range, MMF=mycophenolate mofetil, MPA=microscopic
polyangiitis, MPO=myeloperoxidase, MTX=methotrexate, PR3=proteinase 3, SD= standard
deviation.
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diagnostic delay.
Themean BVAS at diagnosis was comparable in our patients to
that recorded in other large cohorts,[7,13,23,25,28] and was
significantly related to the disease outcome, indicating that the8extent of organ involvement is determinant in patient’s survival.
However, no relationship was found between the initial BVAS
and the occurrence of relapses during the follow-up, in line with
other studies.[7,9] In this sense, the number of disease relapses
varied depending on the type of vasculitis and especially on the
ANCA specificity. Relapses were more like to develop in patients
with GPA and EGPA than in those with MPA, especially
among patients with ENT manifestations, as previously
described,[7,9,11,23,27,29] but above all, patients with C-ANCA-
PR3 were almost twice as likely to experience a relapse as those
with P-ANCA-MPO, consistent with previous reports.[11,24,29–32]
These findings suggest that the ANCA specificity classification
may be more strongly associated with outcomes such as relapse
rate and death than the traditional GPA-MPA separation, as
recently pointed out by Mahr et al.[33]
Concerning therapy, we found significant differences between
treatment administered to patients diagnosed before and after
2000. In this regard, oral CYC was more commonly used for
induction and maintenance therapy in patients diagnosed before
2000 than in those diagnosed later, especially in patients with
granulomatous manifestations due to GPA which often are more
refractory than those vasculitic. According to the European
studies and recommendations,[10–11,34–37] after 2000 most
patients with generalized or severe disease received intravenous
pulses of CYC for induction therapy and switched to other less
toxic immunosuppressant drugs for maintenance therapy, with a
drastic reduction of the total cumulative CYC dose per patient. In
a similar way, patients diagnosed after 2000 received high-doses
of CS (>20mg/day) for a shorter period, followed by a faster
tapering, which lead to an important reduction of the cumulated
dose of CS in the first year. Both facts were associated with
a significant decrease of bacterial and opportunistic infections,
and a lower mortality rate. Of note, we found the strongest
relationship between bacterial and opportunistic infections and
treatment with oral CYC, as reported by other authors.[6,23,38,39]
Our findings confirm that the old CYC-based regimens are
associated with a substantial morbidity, and emphasize the
importance of tailoring treatment regimens according to the
different clinical forms of AAV and disease severity at
presentation. Additionally, our findings highlight the need for
avoiding high-doses of CS therapy for a long time to avoid
infections, as recently proposed.[39,40]
The overall mortality rate in our cohort was 28.7%, quite
similar to that observed in the largest series of patients with AAV
in other countries.[11,13,23–25,33] A higher mortality rate (33.9%)
has recently been reported in Chinese patients, probably due to a
higher percentage of patients with MPA.[41] In our study,
mortality was clearly related to the disease severity and to
secondary bacterial and opportunistic infections associated with
treatment. Of particular interest, we found that the 3 clinical
variables present at diagnosis with the greatest impact in
mortality were renal failure, cardiac involvement, and age older
than 65 years at disease onset. In contrast, ENT involvement
seemed to be a protective factor, suggesting that vasculitic
manifestations are more acute and life threatening than
granulomatous manifestations, which are more likely to have
a chronic course. Bacterial and opportunistic infections were also
independent predictors of death, being both more like to develop
in patients who received high doses of oral CYC and CS,
especially in those patients who developed leucopenia, as
reported by Charlier et al.[39] The most common bacterial
infections were from urinary and respiratory tract, followed by
generalized septicemia, which was significantly more frequent in
Solans-Laqué et al. Medicine (2017) 96:8 www.md-journal.compatients requiring dialysis. Similar results have been found in
former outcome studies.[7,11,13,23–25,35,39–48]
The presence of ANCA at diagnosis conferred an increased risk
of death, suggesting that the absence of ANCA may indicate a
variation in clinical presentation and prognosis, as already
proposed.[11,25] Regarding the ANCA specificities, patients with
P-ANCA-MPO had a worse prognosis than patients with C-
ANCA-PR3 due to an increased risk for severe renal injury and
alveolar hemorrhage, although patients with C-ANCA-PR3
experienced more relapses, our findings being in keeping with
prior reports.[13,30]
Finally, we also found significant differences in terms of
mortality according to the distinct AAV categories, with a worse
prognosis for MPA mainly due to a greater rate of severe renal
failure and an older age of patients at disease onset. Previous
reports have suggested that MPA has a poorer prognosis due to
more severe renal disease.[11,17,24,25,29,41,42] However, the
influence of age at diagnosis is controversial[11,13,17,23,29] and
discrepancies can only be addressed by larger prospective studies.
In contrast to other series,[7,11,29,41] we did not find a high
mortality in patients with lung involvement, neither in the entire
cohort nor according to the different clinical forms, although
pulmonary-renal syndrome was clearly related to a worse
prognosis. Additionally, we did not find significant differences
related to gender.
When compared patients diagnosed before and after 2000, we
found a significant decrease in renal involvement, whereas the
frequency of other organ manifestations did not change
significantly as recently reported by Holle et al,[42] and Eriksson
et al.[49] Of note, the proportion of patients receiving oral CYC
decreased drastically after 2000, and the rate of infections and
mortality declined steadily. Both, the reduction in renal
involvement, as well as the improved outcome after 2000,
may be related to an increased awareness of AAV and their
manifestations, and an earlier introduction of therapy together
with the implementation of less toxic regimens adapted to the
disease activity and stage. Our findings corroborate those from
other studies regarding nearly unchanged organmanifestations at
AAV diagnosis, but a rise in mean age at disease onset,[24,40,49]
and more important, our findings confirm an overall improve-
ment in the prognosis of vasculitis over the last decades, with a
clear decline of mortality after 2000, in line with recent
studies.[42,48–50]
The main strengths of the present study are the recruitment of a
large cohort of patients from the same geographical zone and the
very long-term follow-up. However, some limitations are
recognized such as the retrospective design, and that patients
were treated according to the physician discretion. Despite those
limitations, we believe that this study represents a real picture of
the Spanish patients with AAV.
In summary, this is the first nationwide survey of Spanish
patients with AAV. Patient characteristics and disease activity
were similar in our series to those from other world regions.
Mortality was significantly associated with disease severity at
presentation. In contrast, no relationship was observed between
the initial disease severity and the occurrence of disease relapses.
Patients with positive ANCA, renal involvement, heart failure,
and age older than 65 years at disease onset, had the poorer
prognosis. Treatment-related infections were a general and
independent predictor of death, and were significantly related to
cumulative high doses of CYC and CS. Patients with MPA
showed the highest mortality rate while patients with GPA
showed the highest rate of relapse. An improved outcome, with9reduced morbidity and mortality, was observed in patients
diagnosed after 2000 that was primarily related to the
implementation of less toxic regimens adapted to disease severity.
However, despite these advances a considerable mortality and
treatment-related morbidity remained. Our results underscore
the need for further immunosuppressant, and especially new
therapeutic strategies, which allow reducing CYC and CS
cumulative doses, and improve the prognosis of patients
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